Osteoporosis drug reduces bone loss, tumor size in oral cancer

A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers that erode bone. Dr. Tom Rosol, professor in the department of veterinary biosciences, was the principle investigator in the Ohio State study. The drug treatment also was associated with smaller tumors – an unexpected result. The drug, zoledronic acid, is known by the brand name Zometa. It is designed to inhibit bone resorption, the breaking down of bone caused by the release of a specific kind of cell. Read more: http://researchnews.osu.edu/archive/oralcancer.htm

********

About the College of Veterinary Medicine at Ohio State

Founded in 1885, The Ohio State University College of Veterinary Medicine is ranked fifth in the nation and includes more than 1,000 faculty, staff and students in the Departments of Veterinary Biosciences, Veterinary Clinical Sciences, and Veterinary Preventive Medicine. The Veterinary Medical Center is one of the largest specialty referral centers in the world, with more than 35,000 farm, equine, and companion animal patients each year. A nationally-recognized ambulatory practice and teaching unit in Marysville, Ohio provides farm animal experience to every veterinary student, and the Food Animal Health Research Program in Wooster, OH focuses on detection, control, and prevention of disease. Located on the only campus in the country with a comprehensive medical center offering seven health sciences colleges, we admit up to 162 veterinary students per class, and offer a new comprehensive graduate program in Veterinary and Comparative Medicine as well as a unique Master’s degree in Veterinary Public Health, in partnership with the College of Public Health. http://vet.osu.edu.